Turnkey Employee COVID-19 Testing Program

We design custom testing plans to help your business succeed

The Quest Diagnostics Employee SARS-CoV-2 (COVID-19) Testing Program delivers cost-effective, scalable, and customized testing solutions that are convenient and easy to execute.

With the rise of new variants, these screenings give you and your employees the critical information needed to make better health decisions—even if your team isn't fully vaccinated.

Strategic collaboration

Follow federal and state health and safety guidelines

Keep doors open and maintain productivity

Instill trust with employees as a company dedicated to health and safety

Strengthen your reputation as an employer committed to well-being

End-to-end solutions for businesses of all sizes

With multiple testing and location options, Quest builds affordable solutions tailored to meet the unique needs of your business and number of employees.

Test options

PCR current infection swab test



Rapid antigen swab test



Antibody blood test

Location options

- At Quest
- At work
- At home

Seamless experience

Your employees step through an intuitive online experience, including appointment scheduling, in our MyQuest™ platform.

Your employer administrators can review and verify employee participation status and results through MyQuest. A daily email report displays program engagement and results data.



Supporting your productivity

With new variants continuing to develop, COVID-19 test results can prepare your organization with critical information needed to make important decisions about your staff and their health.

Quest's scalable testing initiatives can help you address employee well-being and workforce safety for the vaccinated and unvaccinated alike.

GET STARTED

Find more information at QuestEmployeeCOVIDTesting.com or contact your Quest representative to begin customizing your organization's Employee COVID-19 Testing Program.

Important information about COVID-19 antibody testing

This COVID-19 antibody test can detect antibodies from a prior or recent infection, regardless of whether symptoms were present. Positive results may also occur after a COVID-19 vaccination, but the clinical significance is not yet known, nor is it known how good this test is at detecting antibodies in those who have been vaccinated. Alternatively, a nucleocapsid test can only detect antibodies from a prior or recent infection.

After a natural infection, current research shows that it may be best to get antibody testing 3 to 4 weeks after symptom onset or known exposure to COVID-19 to increase the opportunity to detect an immune response.

After vaccination, it is not yet known how long it takes to develop antibodies. Antibody testing for the purposes of vaccine decision-making is not currently recommended by the CDC.

If you test too soon, your body may not have produced enough antibodies to be detected by the test, which can lead to a false negative result. This test can sometimes detect antibodies from other related coronaviruses you may have been exposed to, such as a virus that causes the common cold. This can cause a false positive result.

This test should not be used to diagnose an active COVID-19 infection. If an active infection is suspected, molecular or antigen testing is recommended. Learn more about our QuestDirect™ COVID-19 Active Infection Test.

A **negative** antibody test result means that antibodies were not detected in your blood sample. This can have several possible meanings. It could mean that:

- You have not been infected with SARS-CoV-2, or
- You have been infected with SARS-CoV-2, but your antibodies have not reached a sufficient level for the test to be able to detect them, or
- You have been infected with SARS-CoV-2, but there has not been enough time for antibodies to develop (it can take up to 1 to 3 weeks to develop antibodies after someone is infected, sometimes longer).

A **positive** antibody test result means that antibodies were detected in your blood sample. This can have a couple of possible meanings. It could mean that:

- You have been infected with SARS-CoV-2 at some point in the past, or
- Uncommonly, you may have developed antibodies from an earlier infection with a different virus related to SARS-CoV-2 and the laboratory test cannot distinguish between these other virus antibodies and those antibodies generated in response to SARS-CoV-2.

COVID-19 testing statements

- The antibody tests, molecular tests, and antigen tests (together "All tests") have not been FDA cleared or approved;
- All tests have been authorized by FDA under EUAs for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens;
- The antigen tests have been authorized only for the detection of proteins from SARS-CoV-2, and not for any other viruses or pathogens; and
- All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

About the FDA Emergency Use Authorization (EUA) Status

This test has been authorized by the FDA under an Emergency Use Authorization (EUA). This means that while Quest Diagnostics has validated the test and has the data to believe the test and the collection kit are accurate, this test has not been FDA-cleared or -approved; this test has been authorized by FDA under an EUA for use by authorized laboratories; this test has been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens; and, this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(B)(1) of the Act, 21 U.S.C. § 360BBB-3(B)(1), unless the authorization is terminated or revoked sooner. Additional studies need to be conducted for this test and others like it to be FDA cleared or approved.